A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

Sponsor
LG Chem
Study ID
NCT07752875
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LG00313112 — DRUG
    LG00313112 will be administered orally once daily (QD)

Study Details

This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation

Key Dates

First listed
Aug 7, 2026
Start date
Dec 1, 2026
Status verified
Jul 2026
Primary completion
Oct 31, 2032
Completion
Apr 30, 2033

Study Design

Enrollment
250 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose escalation and Backfill

Primary Outcome Measure

Phase 1: Number of participants with dose-limiting toxicities (DLTs) [ Time Frame: Up to 21 days after treatment ]

Find similar trials

Nationwide
Breast cancer trialsColorectal cancer trialsEndometrial cancer trialsEsophageal cancer trialsHead and neck cancer trialsLung cancer trialsOvarian cancer trialsPancreatic cancer trialsOncology trialsBreast oncology trialsWomen's health trialsGI oncology trialsGynecologic oncology trialsENT trialsLung oncology trialsLung disease trials

Related Studies